Literature DB >> 9364658

Management strategies for colorectal liver metastases--Part I.

T J Hugh1, A R Kinsella, G J Poston.   

Abstract

Colorectal cancer is a common malignancy and the incidence of this disease is increasing. Approximately 50% of patients with colorectal cancer die from recurrent disease following an apparently curative resection of the primary tumour and the liver is the most frequent site of relapse. Although only a small proportion of patients will benefit from resection of liver metastases, this form of treatment offers the only possibility of cure. In selected patients, 5-year survival rates of 25-35% may be achieved following liver resection. A poor prognosis after resection of hepatic metastases is likely when there are more than three metastatic deposits, involved resection margins often as a result of ¿wedge' resections, when there is extrahepatic disease, or when there is nodal involvement at the primary tumour site. Regional hepatic artery infusion chemotherapy may provide palliation and possibly even prolongation of survival for some patients with unresectable metastases. Cytoreductive techniques may also provide palliation in selected patients with hepatic metastases unsuitable for resection; cryotherapy is the most promising of these methods.

Entities:  

Mesh:

Year:  1997        PMID: 9364658     DOI: 10.1016/s0960-7404(97)00002-9

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  9 in total

1.  Contrast-enhanced intraoperative ultrasound improves detection of liver metastases during surgery for primary colorectal cancer.

Authors:  Ankur J Shah; Mark Callaway; Michael G Thomas; Meg D Finch-Jones
Journal:  HPB (Oxford)       Date:  2010-04       Impact factor: 3.647

2.  The case for neo-adjuvant chemotherapy. For.

Authors:  Hassan Z Malik
Journal:  Ann R Coll Surg Engl       Date:  2008-09       Impact factor: 1.891

3.  Liver abscess after liver metastasectomy is a poor prognostic factor in patients with colorectal cancer.

Authors:  Yen-Ning Hsu; Chia-Jen Liu; Jen-Kou Lin; Wei-Shone Chen; Tzu-Chen Lin; Shung-Haur Yang; Jeng-Kai Jiang; Shih-Ching Chang; Yuan-Tzu Lan; Chun-Chi Lin; Chueh-Chuan Yen; Jin-Huang Liu; Cheng-Hwai Tzeng; Hao-Wei Teng
Journal:  J Gastrointest Surg       Date:  2011-07-23       Impact factor: 3.452

4.  Comparative study of proteome between primary cancer and hepatic metastatic tumor in colorectal cancer.

Authors:  Bo Yu; Shi-Yong Li; Ping An; Ying-Nan Zhang; Zhen-Jia Liang; Shu-Jun Yuan; Hui-Yun Cai
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

Review 5.  Preoperative selection of patients with colorectal cancer liver metastasis for hepatic resection.

Authors:  Rafif E Mattar; Faisal Al-Alem; Eve Simoneau; Mazen Hassanain
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

6.  Repeated Liver Resection for Colorectal Liver Metastases: A Comparison with Primary Liver Resections concerning Perioperative and Long-Term Outcome.

Authors:  Kristoffer Jönsson; Gerd Gröndahl; Martin Salö; Bobby Tingstedt; Roland Andersson
Journal:  Gastroenterol Res Pract       Date:  2012-08-29       Impact factor: 2.260

7.  Dual Energy Spectral CT Imaging for Colorectal Cancer Grading: A Preliminary Study.

Authors:  Hong-Xia Gong; Ke-Bei Zhang; Lian-Ming Wu; Brian F Baigorri; Yan Yin; Xiao-Chuan Geng; Jian-Rong Xu; Jiong Zhu
Journal:  PLoS One       Date:  2016-02-09       Impact factor: 3.240

Review 8.  Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies.

Authors:  P C Simmonds; J N Primrose; J L Colquitt; O J Garden; G J Poston; M Rees
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

Review 9.  Expanding the Scope of Immunotherapy in Colorectal Cancer: Current Clinical Approaches and Future Directions.

Authors:  Malek Kreidieh; Deborah Mukherji; Sally Temraz; Ali Shamseddine
Journal:  Biomed Res Int       Date:  2020-01-25       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.